New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Rhea-AI Summary
Exicure (Nasdaq: XCUR) announced that completed Phase 2 data for burixafor, a CXCR4 antagonist, will be presented orally at the 67th ASH Annual Meeting on December 8, 2025. The oral presentation (Abstract 1050) reports results from an open-label, multicenter Phase 2 trial (NCT05561751) of burixafor plus G-CSF and propranolol to mobilize hematopoietic progenitor cells in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.
The presentation highlights an excellent safety profile, same-day administration with leukapheresis, and that 18 of 19 patients who chose transplant proceeded to AHCT; many enrolled patients had prior daratumumab exposure. Presenter: Dr. Jack Khouri. Session: Cell Collection and Manufacturing; 5:45–6:00pm EST, Hyatt Regency Ballroom R.
Positive
- None.
Negative
- None.
News Market Reaction 3 Alerts
On the day this news was published, XCUR declined 4.32%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $30M at that time.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will be featured in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.
The presentation will highlight additional patient data from the open-label, multicenter Phase 2 trial (NCT05561751) assessing burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). By blocking CXCR4, burixafor is designed to mobilize hematopoietic progenitor cells from the bone marrow into the peripheral blood, where they can be collected for use in transplantation procedures.
“The combination of burixafor, G-CSF and propranolol demonstrated an excellent safety profile and was able to ensure adequate and efficient mobilization of hematopoietic progenitor cells, with all patients who chose to undergo transplant (18/19) proceeding to AHCT. These are very encouraging results, especially since the majority of the enrolled patients were treated with the anti-CD38 monoclonal antibody daratumumab, which has been associated with lower HPC mobilization in certain studies. The same day administration of burixafor with leukapheresis is also more convenient for patients and may reduce time toxicity,” said Jack Khouri, M.D., Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, study lead investigator, and presenter.
Oral Presentation Details
Abstract Number: 1050
Title: An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma
Presenter: Dr. Jack Khouri, Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Refining CAR-T Cells and Engineered HSPCs; New Approaches to HSPC mobilization
Date and Time: December 8, 2025, 5:45-6:00pm EST
Location: Hyatt - Regency Ballroom R
About Burixafor (GPC-100)
Burixafor (GPC-100) is a highly selective small molecule antagonist of CXCR4, a chemokine receptor that plays a central role in retaining hematopoietic stem cells in the bone marrow niche. By blocking CXCR4, burixafor may enhance the mobilization of these cells into the peripheral blood for collection and use in autologous stem cell transplant (ASCT) procedures. Originally developed by GPCR Therapeutics, Inc., burixafor became part of Exicure’s pipeline following the company’s acquisition in January 2025. In addition to multiple myeloma, burixafor is also being considered in other diseases where improved stem cell mobilization could help enable more efficient and effective treatment approaches, such as sickle cell disease, rare diseases requiring autologous transplant, and cell and gene therapy settings. A chemosensitization trial in AML is also being planned, leveraging burixafor’s mechanism of mobilizing malignant cells from protective bone marrow niches into the peripheral blood, where they may be more effectively targeted by chemotherapy.
About Exicure
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies to address key challenges in hematologic diseases. The company’s lead program, burixafor (GPC-100), is being evaluated for its ability to improve stem cell mobilization in multiple myeloma, sickle cell disease, and in support of cell and gene therapy. It is also being studied as a potential chemosensitizing agent in acute myeloid leukemia (AML). For more information, visit www.exicuretx.com.
Contact:
Exicure, Inc.
847.673.1700 (Tel)
847.556.6411 (Fax)
FAQ
When and where will Exicure present burixafor Phase 2 data at ASH 2025 (XCUR)?
What Phase 2 trial results for burixafor (XCUR) will be reported at ASH 2025?
Who will present Exicure's burixafor data at ASH 2025 and what is the abstract number?
What treatment combination was studied with burixafor in the Phase 2 trial (XCUR)?
How did prior daratumumab exposure factor into the burixafor Phase 2 results for XCUR?
